Afoxolaner Merial

RSS

afoxolaner

Authorised
This medicine is authorised for use in the European Union.

Overview

Afoxolaner Merial is a veterinary medicine used to treat infestations with fleas and ticks, as well as demodectic and sarcoptic mange (skin infestations caused by two different types of mites) in dogs. It may be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites).

Afoxolaner Merial contains the active substance afoxolaner. This medicine is the same as NexGard, which is already authorised in the European Union (EU). The company that makes NexGard has agreed that its scientific data can be used for Afoxolaner Merial (‘informed consent’).

This EPAR was last updated on 07/06/2019

Authorisation details

Product details
Name
Afoxolaner Merial
Agency product number
EMEA/V/C/005126
Active substance
afoxolaner
International non-proprietary name (INN) or common name
afoxolaner
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP53BE01
Publication details
Marketing-authorisation holder
Merial
Date of issue of marketing authorisation valid throughout the European Union
20/05/2019
Contact address

29 Avenue Tony Garnier
69007 Lyon
France

Product information

20/05/2019 Afoxolaner Merial - EMEA/V/C/005126 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ECTOPARASITICIDES FOR SYSTEMIC USE

Therapeutic indication

Treatment of flea (Ctenocephalides felis and C. canis) infestations. The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Treatment of tick (Dermacentor reticulatus, Ixodes ricinus, Rhipicephalus sanguineus) infestations.

Treatment of demodicosis (caused by Demodex canis).

Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis).

Assessment history

How useful was this page?

Add your rating